DOSEGUY

Fasoracetam

weak data

Also seen as: AEVI-001, NFC-1, NS-105, LAM-105, faso

The Dose Guy’s verdict
Sep 1, 2026
2 sources

Fasoracetam stands a step above its racetam siblings for one reason: it actually reached a human trial and came out with a signal. Thirty adolescents, open-label after a single-blind placebo week, real improvement on a real rating scale. Only phenylpiracetam has similar standing among the racetams. The catch: those 30 were selected for mutations in metabotropic glutamate receptor genes, the exact pathway fasoracetam hits, and nobody buying this off a vendor site has been genotyped. The evidence is thin but it exists, and that makes it the racetam I’d reach for if I were reaching for one.

Would I take it?Cautiously. One real trial is more than most racetams can show.

What it is

A racetam-family compound that works through metabotropic glutamate receptors rather than the AMPA-receptor story most racetams tell. Fasoracetam hits group I, II, and III mGluR subclasses, and in animal work it increases cortical acetylcholine release, the pathway the community associates with its focus effects. The second mechanism the community cares about is GABA-B receptor upregulation, reported in animal work and leaned on by people tapering off phenibut or baclofen who want to reset receptor sensitivity. That use case rests on animal data and consistent anecdote, not a human trial, but the demand is real.

What the research shows

One real human study, small and uncontrolled, plus vintage PK work:

In 30 adolescents with ADHD and mGluR gene variants, five weeks of fasoracetam improved mean CGI-Improvement from 3.79 to 2.33 and CGI-Severity from 4.83 to 3.86, both with p less than 0.001. Adverse-event rates did not differ between the placebo week and active-drug weeks.Nat Comms 2018 · ADHD · n=30
After a single 100 mg oral dose in humans, elderly men showed higher exposure than young men, with mean AUC of 24.6 versus 14.4 microgram hours per mL, reflecting slower clearance with age.Ann Pharmacother 1999 · PK · n=13
No large controlled efficacy trial has followed the 2018 ADHD study. Development stalled, and the compound lives on as a community nootropic.as of Aug 2026

Realistic protocols

Two distinct use cases, two different approaches. For general cognition and focus, the community runs 20 to 100 mg daily, usually sublingual for faster onset and better absorption. Most people start at 20 mg and hold if they notice the effect. Higher doses don’t add much for most users, and the ADHD trial dosed far above community practice, up to 400 mg twice daily, because it was testing a clinical population. For the GABA-B upregulation use, the same dose range but the run is shorter and more intentional: a couple of weeks alongside a taper from phenibut or baclofen, treating the fasoracetam as a bridge to restore receptor sensitivity. Either way, pair it with a choline source like alpha-GPC, the standard racetam pairing, because fasoracetam draws on acetylcholine and you’ll feel the deficit as a headache if choline is low.

Focus use20–100 mg/daySublingual preferred. Start at 20 mg and hold if it works.
GABA-B reset20–100 mg/dayShort run alongside a taper. Animal and anecdotal basis, no human trial for this use.
Choline pairing+ alpha-GPCStandard racetam advice. Prevents the acetylcholine-depletion headache.

Side effects

Generally mild, consistent with the racetam class:

commonHeadache, the classic racetam tell when choline is insufficient. A choline source fixes it.
anecdotalSubtle mood lift or reduced social anxiety, consistent with the GABA-B angle.
anecdotalOccasional irritability or overstimulation at higher doses, more common above 100 mg.
unknownLong-term safety data does not exist. The ADHD trial ran five weeks in 30 people. Everything past that is community mileage.

Where to buy

Disguised Research–
$49.99 / unit
⚠ ⚠ Unreachable since Sep 11
✓ verified Sep 8
Read review →
Visit →

Prices move. Links are affiliate links; they never change a ranking, and scores are set before the deal exists.